Abstract |
We investigated the antitumoral activity of Dabis Maleate given on different dosage schedules and as continuous infusion in a murine reticular cell sarcoma M5076 (M5) and in a subline made resistant to cyclophosphamide and other nitrogen mustards (M5/CTX). The therapeutic index of Dabis Maleate was clearly better when the drug was given as a continuous 72-h infusion. Dabis Maleate appeared non-cross-resistant to cyclophosphamide and this property renders it interesting for further clinical development.
|
Authors | G Tagliabue, S Filippeschi, H Hendricks, M D'Incalci |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 3
Issue 3
Pg. 233-6
(Mar 1992)
ISSN: 0923-7534 [Print] England |
PMID | 1586622
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Bridged Bicyclo Compounds
- Bridged Bicyclo Compounds, Heterocyclic
- Quaternary Ammonium Compounds
- NSC 262266
- Cyclophosphamide
|
Topics |
- Animals
- Bridged Bicyclo Compounds
(pharmacology)
- Bridged Bicyclo Compounds, Heterocyclic
- Cell Division
(drug effects)
- Cyclophosphamide
(pharmacology)
- Drug Administration Schedule
- Drug Resistance
- Female
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, pathology)
- Mice
- Mice, Inbred C57BL
- Neoplasm Transplantation
- Quaternary Ammonium Compounds
(pharmacology)
- Tumor Cells, Cultured
|